Monitor the next 10-Q or 10-K filing to assess whether the going concern uncertainty from FY 2024 has been resolved and whether auditor transition impacts financial reporting timelines or tone.
Price Chart
Executive Summary
Damora Therapeutics (DMRA) dismissed EY Denmark as its auditor and appointed EY US as the new independent registered public accounting firm. The change was approved by the Audit Committee, with no reported disagreements or reportable events with the former auditor.
Key Facts
- EY Godkendt Revisionspartnerselskab (EY Denmark) was dismissed as DMRA's auditor effective April 17, 2026, after serving since 2019.
- Ernst & Young LLP (EY US) was appointed as the new auditor on the same date.
- The audit report for FY 2024 included a going concern explanatory paragraph; FY 2025 audit was unqualified.
- No disagreements or reportable events were disclosed between DMRA and EY Denmark during the past two fiscal years or interim period.
- EY Denmark confirmed agreement with the disclosures in its letter filed as Exhibit 16.1.
Financial Impact
No immediate financial impact disclosed. The FY 2024 audit report included a going concern qualification, which may reflect prior liquidity concerns.
Risk Factors
- Auditor changes can signal underlying financial or governance issues, though none were disclosed here.
- The prior going concern qualification for FY 2024 raises questions about the company's financial stability, which should be monitored in future filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-163909 |
| Document: dmra-ex16_1.htm | 0001193125-26-163909 |
| Document: 0001193125-26-163909-index-headers.html | 0001193125-26-163909 |
| Document: 0001193125-26-163909-index.html | 0001193125-26-163909 |
| Document: 0001193125-26-163909.txt | 0001193125-26-163909 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $20.26 $19.27 | ▼ −4.86% | ▼ −3.37% | $21.53 (+6.29%) |
Sep 28, 2026 28d ago | Insider Buy | $20.75 $20.22 | ▼ −2.55% | ▼ −3.76% | $21.53 (+3.76%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $30.31 | ▼ −1.37% | ▲ +0.60% | $21.53 (−29.94%) |
Aug 10, 2026 10w ago | Press Release | $30.36 $31.80 | ▼ −4.74% | ▼ −5.15% | $21.53 (+29.08%) |
Jul 20, 2026 13w ago | 8-K | $32.99 $29.44 | ▼ −10.76% | ▼ −9.53% | $21.53 (−34.74%) |
Apr 20, 2026 26w ago | 8-K | $26.82 $24.23 | ▼ −9.66% | ▼ −10.74% | $21.53 (−19.72%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $24.27 | ▲ +5.29% | ▲ +8.86% | $21.53 (−6.59%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $25.50 | ▲ +40.57% | ▲ +42.72% | $21.53 (+18.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers